Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Non-Current Assets: 2021-2024

Historic Other Non-Current Assets for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $24,000.

  • Amylyx Pharmaceuticals' Other Non-Current Assets rose 418.67% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 418.67%. This contributed to the annual value of $24,000 for FY2024, which is 96.58% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Other Non-Current Assets of $24,000 as of FY2024, which was down 96.58% from $701,000 recorded in FY2023.
  • Amylyx Pharmaceuticals' 5-year Other Non-Current Assets high stood at $701,000 for FY2023, and its period low was $24,000 during FY2024.
  • In the last 3 years, Amylyx Pharmaceuticals' Other Non-Current Assets had a median value of $466,000 in 2022 and averaged $397,000.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Other Non-Current Assets surged by 133.00% in 2022 and then slumped by 96.58% in 2024.
  • Amylyx Pharmaceuticals' Other Non-Current Assets (Yearly) stood at $200,000 in 2021, then soared by 133.00% to $466,000 in 2022, then spiked by 50.43% to $701,000 in 2023, then tumbled by 96.58% to $24,000 in 2024.